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Docetaxel and Irinotecan in Recurrent
or Metastatic Head and Neck Cancer
A Phase 2 Trial of the Eastern Cooperative Oncology Group
Athanassios Argiris, MD1; Ashley Buchanan, MS2; Bruce Brockstein, MD3; Jill Kolesar, PharmD4;
Musie Ghebremichael, PhD5; Michael Pins, MD6; Kristine Hahn, PharmD4; Rita Axelrod, MD7;
and Arlene Forastiere, MD8
BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma
of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of
patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic
SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients
received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on Days 1 and 8, every 21 days, until
disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in
serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyz-
able: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B);
73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%)
patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median pro-
gression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months
in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high
serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P ¼ .085).
CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected
patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or
platinum-based regimens. Cancer 2009;115:4504–13. VC 2009 American Cancer Society.
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More than 45,000 new cases of head and neck cancer are diagnosed annually in the United States.1
Patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN) have a
poor prognosis.2 Cisplatin-based combination regimens given as first-line treatment of recurrent or meta-
static SCCHN result in objective response rates of about 30% and median overall survival (OS) of 8 to
9 months.3 More recently, the epidermal growth factor receptor inhibitors were introduced in the systemic
therapy of SCCHN.4 However, at present time, there is no standard regimen for the second-line treatment of
recurrent or metastatic SCCHN.
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Docetaxel is a semisynthetic taxane that acts as a mi-
totic spindle poison by promoting microtubule assembly
but inhibiting tubulin depolymerization, which disrupts
cell division. The major toxicity with the 3-week schedul-
ing of docetaxel is neutropenia, which is ameliorated by
weekly administration.5 Clinical studies have documented
the efficacy of docetaxel in many solid tumors, even after
previous treatment with paclitaxel.6 Weekly docetaxel at a
dose of 30 mg/m2 was highly active in a phase 2 trial in
chemonaive recurrent or metastatic SCCHN with a
reported response rate of 42% and median OS of 11.3
months.7 A phase 2 randomized study of weekly docetaxel
versus methotrexate showed higher response rates for
docetaxel but comparable survival rates.8
Irinotecan is a water-soluble analogue of camptothe-
cin that inhibits topoisomerase I, a critical enzyme for
DNA replication and transcription. Irinotecan is metabo-
lized in the liver to SN-38, an active metabolite that
undergoes glucuronidation in the liver through uridine
diphosphate glucuronosyltransferase isoform 1A1
(UGT1A1) to the relatively inactive SN-38G (SN-38 glu-
curonide). The major toxicities of irinotecan are neutro-
penia and diarrhea. Polymorphisms in UGT1A1 have
been reported to result in increased incidence of irinote-
can-related toxicities.9,10 A phase 2 study of irinotecan
given weekly at 125 mg/m2 for 4 weeks followed by
2 weeks of rest in recurrent or metastatic SCCHN
reported a response rate of 26% in 19 evaluable patients.11
Because of toxicity, 14 subsequent evaluable patients were
treated at a lower dose of 75 mg/m2, and the schedule was
altered to 2 weeks on, 1 week off. The response rate in this
cohort was 14%. However, irinotecan had no significant
activity when given in the second-line therapy setting.11
The combination of irinotecan and docetaxel is sup-
ported by preclinical observations and showed promising
activity in early clinical investigations in solid tumors.12 A
phase 1 clinical trial established the recommended phase 2
dose as irinotecan 60 mg/m2 and docetaxel 35 mg/m2 on
Days 1 and 8, repeated every 21 days.13 On the basis of
these observations, we designed a phase 2 study to investi-
gate the antitumor activity and toxicities with irinotecan
and docetaxel in patients with recurrent or metastatic
SCCHN. We also examined the potential correlation
between UGT1A1 genotype and toxicity of the regimen.
Cyclooxygenase-2 (COX-2) and vascular endothelial
growth factor (VEGF) are overexpressed in SCCHN.14-16
Therefore, we also sought to evaluate the expression of
COX-2 and VEGF in tumor tissue as well as serum
VEGF as predictors of antitumor efficacy.
MATERIALS AND METHODS
Patient Selection
Eligible patients were 18 years of age with recurrent or
metastatic SCCHN considered incurable by means of
locoregional therapies, Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1, and measur-
able disease according to Response Evaluation Criteria in
Solid Tumors.17 Patients were enrolled simultaneously in
2 groups. Group A patients could not have received prior
chemotherapy for locally recurrent or metastatic disease
but may have received chemotherapy as part of primary cu-
rative therapy, if completed>6months before registration.
Group B patients had to have received 1 prior chemother-
apy regimen for locally recurrent or metastatic disease, or
chemotherapy as part of primary curative therapy <6
months before registration. Prior paclitaxel was permitted,
but prior docetaxel or irinotecan at any time was not
allowed. Other inclusion criteria included adequate hema-
tologic and liver function test parameters and no peripheral
neuropathy of grade 2 or worse. All patients signed
informed consent, and the protocol was approved by each
institution’s human investigations committee.
Treatment Plan
Docetaxel (Sanofi-Aventis, Bridgewater, NJ) was admin-
istered as a 60-minute intravenous infusion at a dose of 35
mg/m2 followed by the administration of irinotecan
(Pharmacia Corporation/Pfizer Inc, New York, NY)
intravenously over 30 minutes at a dose of 60 mg/m2.
Chemotherapy was given on Days 1 and 8 of a 21-day
schedule and continued until progression of disease, unac-
ceptable toxicity, or patient withdrawal. Patients received
antiemetics and dexamethasone for a total of 3 doses,
12 hours before, 30 minutes before, and 12 hours after
docetaxel. All toxicities were graded according to the
National Cancer Institute’s Common Toxicity Criteria
(version 2.0). A dose reduction of docetaxel to 30 mg/m2
and irinotecan to 50 mg/m2 was allowed. High-dose
loperamide, tincture of opium, and octreotide were used
for treatment of delayed diarrhea.
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Patient Assessments and Monitoring
Patients were evaluated by computed tomography (CT)
of the chest and abdomen and CT or magnetic resonance
imaging of the neck at baseline, within 4 weeks of registra-
tion, and then after every 3 cycles (9 weeks). Bone scan
was performed at baseline and then as clinically indicated.
When a patient was deemed to have an objective response,
tumor measurements were to be repeated 4 to 6 weeks
later to confirm the response. Complete blood counts
were obtained on Days 1 and 8, and serum chemistry tests
were on Day 1 of each cycle.
Statistical Methods
The primary endpoint was the overall objective response
rate, which was defined as the proportion of patients with
complete or partial response defined by Response Evalua-
tion Criteria in Solid Tumors17 among eligible, treated
patients, including patients not evaluable for response. In
the first stage of a 2-stage design, 14 eligible patients (16
total to allow for a 10% ineligibility rate) were to be
accrued to each of the 2 cohorts. Response rates of 40%
and 20% were considered promising in Groups A and B,
respectively. If at least 4 responses were seen in Group A
and at least 1 response in Group B, accrual would con-
tinue to the second stage to accrue 18 additional patients
in each group (ie, the total accrual goal was 32 eligible
patients for each group). OS was defined as the time from
registration to the date of death or last follow-up. Progres-
sion-free survival (PFS) was defined as the time from
registration to disease progression or death from any cause
or last follow-up. Two-stage confidence intervals, 2-stage
power calculations, and the 2-stage stopping rules were
used to analyze the data in regard to the study’s 2-stage
design.18 Fisher exact test19 was used to analyze the con-
tingency tables of response and to compare the distribu-
tion of categorical data between groups. Cochran-Mantel-
Haenszel test was used to assess the association between
response and categories adjusting for the differences in
prior treatment status. The Wilcoxon rank sum test20 was
used to compare the distribution of continuous data
between the 2 groups. Kaplan-Meier curves were plotted
for OS and PFS.21 The log-rank test statistic was used to
compare survival curves between categories, and a strati-
fied log-rank test was used to adjust for differences in prior
treatment status. Moreover, logistic and Cox proportional
hazards regression models,22 respectively, were used to
model objective response and survival data on covariates
of interest while adjusting for prior treatment status. Meh-
ta’s exact test for ordered categorical data was used to test
for associations between UGT1A1 genotype and toxicity
severity.23 Two-sided P values are reported for all the sta-
tistical tests used in the analysis.
Correlative Studies
Immunohistochemistry for COX-2 and VEGF
Immunohistochemistry for the determination of
COX-2 and VEGF in archival formalin-fixed paraffin-
embedded tumor tissue was performed using commer-
cially available antibodies: a monoclonal mouse antihu-
man COX-2 (Cayman Chemical, Ann Arbor, Mich), at
1:50 dilution, and a polyclonal rabbit antihuman
VEGF(A-20) (Santa Cruz Biotechnology, Santa Cruz,
Calif), at 1:500 dilution. For VEGF cytoplasmic staining,
tumors were assigned a score of either 0 (negative), 1þ
(weak,<1% of cells), 2þ (medium, 1%-10% of cells), or
3þ (strong, >10% of the tumor cells); for COX-2 mem-
brane staining, tumors were assigned a score of either 0
(negative, or faint in <10%), 1þ (faint, >10% of cells),
2þ (moderate, >10% of cells), or 3þ (strong, complete
in >10% of the tumor cells). The median intensity of
VEGF was used to classify the cases into low (<1.5) or
high (>1.5) VEGF categories. A cutoff of 2þ COX-2
intensity was used to classify the cases into low (2) or
high (>2) categories.
Serum VEGF
Quantitative determination of human VEGF con-
centrations in serum was performed by enzyme-linked
immunosorbent assay using either kit DY293B or
DVE00 from R&D Systems (Minneapolis, Minn). Sam-
ples were measured in duplicate, and VEGF standard was
included with every group of sera tested. The coefficient
of variation for VEGF standard was 10% (62.5-2000
pg/mL). The median serum VEGF score was used to clas-
sify the cases into low (394) or high (>394) serum
VEGF categories.
UGT1A1 genotyping
Genomic DNA for UGT1A1 determination was
prepared from whole blood (100-200 mL) using the
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QIAmp blood kit (Qiagen, Valencia, Calif). A standard
polymerase chain reaction was performed using
UGT1A1-specific primers that flanked the TATA region
with the forward primer biotinylated. TA repeat number
was determined by pyrosequencing with a PSQ 96MA
pyrosequencer and software (Biotage, Uppsala, Sweden)
by standard methods.24,25 Genotypes for the cell lines
DU145 and MCF-7 were previously determined to be 6
of 7 and 7 of 7, respectively. DU145 (n ¼ 7) and MCF-7
(n ¼ 3) were assayed with 100% accuracy for each gene.
One or both of these cell lines were included as a positive
control along with patient samples in each pyrosequenc-
ing reaction.
RESULTS
From October 2002 until August 2004, a total of 54
patients were enrolled, 18 in Group A and 36 in Group B.
Two patients in Group B never started treatment; 1
patient withdrew consent and another signed consent but
died before starting treatment. Four patients were reclassi-
fied with respect to their prior chemotherapy, 1 from
Group A to B and 3 from Group B to A. As a result, there
were 52 analyzable patients; 20 in Group A, and 32 in
Group B. Although 4 objective responses were observed
in Group A, 1 was not confirmed by repeat imaging, and
accrual did not proceed to the second stage for that group.
Patient characteristics and prior treatments are shown in
Tables 1 and 2. Patients received a median of 3 cycles of
irinotecan and docetaxel (range, 1-10 cycles).
Response
In Group A, there were 3 partial responses for a response
rate of 15% (90% confidence interval, 4.2%-34.4%) and
in Group B, there was 1 partial response for a response
rate of 3.1% (90% confidence interval 0.004%-19.6%).
There was an additional unconfirmed partial response in
each group (Table 3). Of the 52 patients, 13 were uneva-
luable because no post-treatment measurements were
taken; 4 patients had symptomatic deterioration, 1 patient
died before first follow-up assessment, 4 patients with-
drew from study after only 1 cycle of treatment because of
toxicity, 3 patients had inadequate data or were lost to fol-
low-up, and 1 patient did not have a consistent method of
evaluation.
OS and PFS
At the time of this analysis, all patients but 1 have pro-
gressed or died. For patients in Group A, the median OS
was 8.2 months, and for patients in Group B, the median
OS was 5.0 months (Table 3 and Fig. 1). In Group A, the
median PFS was 3.3 months, and in Group B, the median
PFS was 1.9 months. No baseline characteristic was found
to be statistically significant in predicting survival, but the
study was not powered to identify such factors.
Toxicity
Three deaths, all in Group B, were deemed possibly
related to study treatment. Two were because of sepsis, in
1 case associated with neutropenia, diarrhea, and dehydra-
tion. The third patient presented after 2 weeks of treat-
ment on cycle 1 with fever, chills, and dyspnea, refused
treatment, and died at home 2 days later from presumed
pneumonia. Two other patients, 1 in each group, died
from grade 5 carotid hemorrhage without thrombocyto-
penia, which was attributed to disease progression. The
most common grade 3 or 4 events in the 2 groups com-
bined were diarrhea (grade 3, 21%; grade 4, 4%), fatigue
(grade 3, 17%), anorexia (grade 3, 8%; grade 4, 4%), and
neutropenia (grade 3, 8%; grade 4, 13%). Only 1 patient
(2%) had febrile neutropenia (Table 4).
COX-2 and VEGF
Forty-one patients consented for the use of their samples
for correlative studies. COX-2 and VEGF tumor expres-
sion data were available for 31 and 29 cases, respectively.
We did not detect any significant differences in OS or
PFS between groups on the basis of COX-2 or VEGF
expression, presumably because of small sample sizes (Ta-
ble 5). Baseline serum VEGF data were available for 18
patients. The association between serum VEGF at base-
line and median PFS is shown in Table 5. Patients with
high baseline VEGF levels had a median PFS of 2.84
months versus 1.73 months for patients with low VEGF
(P¼ .085, using stratified log-rank test).
UGT1A1 Gene
We explored the association between polymorphisms in
the UGT1A1 gene and race, neutropenia, diarrhea, and
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Men 15 75.0 26 81.3
Women 5 25.0 6 18.8
Race
White 20 100.0 26 83.9
Black 0 0.0 5 16.1
Not specified 0 1
ECOG performance status
0 8 40.0 7 21.9
1 12 60.0 25 78.1
Primary tumor site
Oral cavity 5 25.0 7 21.9
Oropharynx 5 25.0 8 25.0
Hypopharynx 1 5.0 3 9.4
Larynx 5 25.0 11 34.4
Salivary gland, parotid 0 0.0 1 3.1
Unknown primary 1 5.0 1 3.1
Other 3 15.0 1 3.1
Tumor cell differentiation
Well differentiated 2 12.5 5 20.8
Moderately differentiated 9 56.3 13 54.2
Poorly differentiated 5 31.3 6 25.0
Unknown 4 8
Weight loss in previous 6 months
<5% of body weight 12 70.6 14 46.7
5-<10% of body weight 3 17.6 5 16.7
10-<20% of body weight 1 5.9 8 26.7
‡20% of body weight 1 5.9 3 10.0
Unknown 3 2
Smoking history
Never smoked 2 10.0 3 10.3
Pipe or cigar smoker only 0 0.0 1 3.4
Cigarette smoker <20 pack-years 2 10.0 2 6.9
Cigarette smoker 20-40 pack-years 4 20.0 11 37.9
Cigarette smoker >40 pack-years 12 60.0 12 41.4
Unknown 0 3
Alcohol consumption
<10 ounces of whiskey/wk* 14 73.7 20 69.0
10-32 ounces of whiskey/wk* 3 15.8 4 13.8
>32 ounces of whiskey/wk* 2 10.5 5 17.2
Unknown 1 3
Metastatic site involvement
Yes 13 65.0 25 78.1
No 7 35.0 7 21.9
ECOG indicates Eastern Cooperative Oncology Group.
*Or equivalent.
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any toxicity among 35 patients with available data. There
were no statistically significant differences in the pattern
of worst degree toxicity, or in the grade intensity of neu-
tropenia or diarrhea by TA repeat category (data not
shown).
DISCUSSION
We evaluated the combination of docetaxel and irinote-
can, a novel non–platinum-containing regimen, in the
first- or second-line treatment of patients with recurrent
or metastatic SCCHN. Both drugs were given on a weekly
schedule of administration based on prior phase 1 experi-
ence.13 Phase 2 trials of docetaxel and irinotecan, using
weekly or every 3 weeks schedules of administration, have
been conducted in many other solid tumors.26-33 To the
best of our knowledge, this is the only phase 2 study of
docetaxel and irinotecan in recurrent or metastatic
SCCHN. Although objective responses were observed,
the prespecified criteria for efficacy were not met. In the
first-line setting (Group A), 4 objective responses were
observed as required per study design, but 1 was uncon-
firmed, which did not allow the study to accrue beyond
the first stage of a 2-stage Simon design. The statistical
design assumed a target response rate of 40% in Group A,
which in retrospect was rather high for the cooperative
group setting and with the application of Response Evalu-
ation Criteria in Solid Tumors. Other cooperative group
studies in comparable patient populations, such as E5397
and E1595, showed that single-agent chemotherapy with
cisplatin achieves an objective response rate of 10% and
median survival of 8 months (E5397),34 and that cisplatin
doublets (cisplatin/5-FU or cisplatin/paclitaxel) result in
objective response rates of 26% to 27% and median sur-
vival of 8.1 to 8.7 months (E1395).3 In the current study,
docetaxel and irinotecan produced a response rate of 17%
(22% counting an unconfirmed response), median PFS of
3.3 months, and median OS of 8.2 months. Therefore,
survival results with docetaxel and irinotecan may be com-
parable to platinum-based combinations.





No. % No. %
Previous chemotherapy 6* 30.0 32 100.0
Received curative therapy only 6 100.0 20 62.5
Received palliative therapy only — — 7 21.9
Both palliative and curative — — 5 15.6
Prior paclitaxel 5 25.0 26 81.3
Prior biologic treatment 0 0.0 1 3.1
Prior surgery 17 85.0 22 68.8
Prior radiotherapy 18 90.0 29 90.6
*Chemotherapy as part of potentially curative therapy >6 months earlier.
Table 3. Efficacy Results: Response Rate,





Best confirmed response* No. (%) No. (%)
Partial response 3 (15.0) 1 (3.1)
Stable disease 4 (20.0) 9 (28.1)
Progression 8 (40.0) 14 (43.8)








90% CI 3-30 2-9
Overall survival, median, mo 8.2 5.0
90% CI 3.9-3.2 3.4-9.1
1-Year overall survival (35) (16)
90% CI 21-58 8-31
CI indicates confidence interval.
* One patient included in the stable disease group in each cohort had
unconfirmed partial response.
FIGURE 1. Kaplan-Meier estimation of overall survival is
shown by patient group; chemotherapy naive, Group A (n ¼
20), had a median survival of 8.2 months; previously treated,
Group B (n ¼ 32), had a median survival of 5 months.
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Table 4. Grade 3-5 Toxicities With Irinotecan and Docetaxel
Group A, n520 Group B, n532
Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
Hemoglobin — — — — — — 1 3% — — — —
Leukocytes 4 20% 2 10% — — 5 16% 2 6% — —
Lymphopenia — — — — — — 1 3% — — — —
Neutrophils 2 10% 4 20% — — 2 6% 3 9% — —
Transfusion of packed red blood cells 1 5% — — — — 3 9% — — — —
Hypotension — — — — — — — — 2 6% — —
Thrombosis/embolism — — — — — — 1 3% — — — —
Cardiac, other — — — — — — — — 1 3% — —
Fatigue 2 10% — — — — 7 22% — — — —
Fever — — — — — — 1 3% — — — —
Prothrombin time — — — — — — 1 3% — — — —
Anorexia 1 5% 1 5% — — 3 9% 1 3% — —
Dehydration 6 30% — — — — 3 9% — — 1 3%
Gastritis 1 5% — — — — — — — — — —
Stomatitis 1 5% — — — — — — — — — —
Nausea — — — — — — 2 6% — — — —
Vomiting 1 5% — — — — 1 3% 1 3% — —
Diarrhea 8 40% 1 5% — — 3 9% 1 3% — —
Gastrointestinal bleeding 1 5% — — — — — — — — — —
Alkaline phosphatase 1 5% — — — — — — — — — —
Hypoalbuminemia — — — — — — 1 3% — — — —
Febrile neutropenia 1 5% — — — — — — — — — —
Infection with grade 3-4 neutropenia 1 5% 1 5% — — — — 1 3% 1 3%
Infection with unknown neutrophil count — — — — — — 1 3% — — — —
Infection without neutropenia — — — — — — — — 2 6% 1 3%
Hypokalemia 1 5% — — — — 1 3% — — — —
Hyponatremia 7 35% — — — — 3 9% — — — —
Depressed level of consciousness — — — — — — 2 6% — — — —
Dizziness/lightheadedness — — — — — — 1 3% — — — —
Anxiety/agitation 1 5% — — — — 1 3% — — — —
Hypoxia 1 5% — — — — — — — — — —
Pleural effusion 1 5% — — — — — — — — — —
Pulmonary, other — — 1 5% — — — — — — — —
Syncope — — — — — — 1 3% — — — —
Abdominal pain — — — — — — 1 3% — — — —
ARDS — — — — — — — — 1 3% — —
Dyspnea — — — — — — 1 3% 1 3% — —
Creatinine — — 1 5% — — 1 3% 1 3% — —
Worst degree 9 45% 6 30% — — 14 44% 5 16% 3 9%
ARDS indicates acute respiratory distress syndrome.
Table 5. Progression-Free Survival by COX-2/VEGF Expression








Low 20 2.00 2.89 1.86
High 19 2.73 3.56 1.87
Tumor VEGF .9739
Low 15 2.10 3.22 1.95
High 24 2.35 3.68 1.87
Serum VEGF .0853
Low 9 1.84 1.91 1.81
High 9 2.73 7.2 2.73
COX-2 indicates cyclooxygenase-2; VEGF, vascular endothelial growth factor.
* Stratified log-rank P value (all patients).
The group of patients treated in the second-line set-
ting (Group B) is 1 of the largest that have been studied so
far, and it was characterized by a high representation of
patients with distant metastasis (78%) and previous treat-
ment with paclitaxel (81%). In these patients, the efficacy
of docetaxel and irinotecan, with a response rate of 3%
(6% counting an unconfirmed response), median PFS of
1.9 months, and median OS of 5.0 months, cannot be
considered satisfactory. As a single agent, irinotecan may
be inactive in previously treated recurrent or metastatic
SCCHN,11 whereas data with single-agent docetaxel is
limited in a similar setting, but activity has been
reported.35
The docetaxel and irinotecan regimen we used in
our study was associated with expected toxicities, which
were predominantly nonhematologic, including diarrhea,
anorexia, and fatigue. Although most of the patients had
received paclitaxel in the past, grade 3 or 4 neuropathy
was not seen. Grade 4 toxicity was observed in 30% of
chemotherapy-naive patients in this study versus 42% and
50% with cisplatin/paclitaxel and cisplatin/5-FU, respec-
tively, in E1395, whereas there was no treatment-related
death versus 5% and 7% with cisplatin/paclitaxel and cis-
platin/5-FU, respectively.3 However, there were some dif-
ferences in the toxicity criteria used between these ECOG
studies, so the rates of grade 3 and 4 toxicities may not be
directly comparable. Polymorphisms in the UGT1A1
gene have demonstrated racial variability and have been
shown to be associated with differences in observed toxic-
ities among patients treated with irinotecan. We could
not demonstrate any correlation of toxicities with
UGT1A1 genotypes, possibly because of the small sample
size, or the low dose of irinotecan used in this study.
COX-2 and VEGF are overexpressed in SCCHN
and have been suggested as potential predictors of out-
come.14-16,36 Moreover, COX-2 expression has been
reported to correlate with the expression of VEGF in
SCCHN. On the basis of preclinical observations, it has
been proposed that docetaxel may have an antiangiogenic
effect.37 We elected to assess VEGF as well as COX-2 on
baseline tumor tissue and attempted to associate its
expression with outcome. However, in the clinical setting
examined, we could not demonstrate that expression of ei-
ther COX-2 or VEGF correlated with worse survival, pos-
sibly because of insufficient sample size.38 Patients with
high serum VEGF levels had a trend toward improved
PFS with docetaxel and irinotecan versus patients with
low levels at baseline, an observation that may require fur-
ther evaluation in subsequent studies.
The docetaxel and irinotecan regimen we used was
feasible and was associated with a toxicity profile poten-
tially favorable to cisplatin-based combinations. However,
its antitumor activity is unlikely to be superior to plati-
num-based combinations in the first-line treatment of
recurrent or metastatic SCCHN, whereas its antitumor
activity in the second-line setting was rather disappoint-
ing. It has been reported that selected patients, such as
those with tumors with high levels of excision repair cross
complementation Group 1, may benefit less from plati-
num-based chemotherapy.39 Whether docetaxel and iri-
notecan, a nonplatinum doublet, will be beneficial in
selected patients, such as those with tumors with high
excision repair cross complementation Group 1, is a
worthwhile hypothesis to be evaluated in future clinical
trials in patients with SCCHN.
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